Trial
NCT03722498
Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Sun Yat-sen University
Collaborators
Guangzhou No.12 People's Hospital; Kaiping Central Hospital
Condition
Hepatocellular Carcinoma
Intervention
HAIC of FOLFOX
Why stopped
No patients join
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-11